Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Dentz, Bernard (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S399000, C549S400000, C549S403000, C549S406000
Reexamination Certificate
active
08008344
ABSTRACT:
The invention relates to a compound represented by the following formula (I):and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-neurodegenerative diseases and human spinal muscular atrophy (SMA).
REFERENCES:
patent: 6174905 (2001-01-01), Suzuki et al.
patent: 6888027 (2005-05-01), Watkins et al.
patent: 7169801 (2007-01-01), Bressi et al.
patent: 1640371 (2009-03-01), None
patent: 0138322 (2001-05-01), None
Yakushijin et al, Heterocycles vol. 4 (4), p. 397-402 (1980).
Chauhan et al, Planta, Medica, p. 221-222 (1987).
Phommart et al, J. of Natural Products, vol. 68, p. 927-930 (2005).
Hsiang-Yu Lin et al.,; Targeting Histone Deacetylase in Cancer Therapy, Journal, Jan. 31, 2006; pp. 397-413; Wiley Periodicals.
Paul A. Marks et al.,; Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells; Journal; Aug. 2, 2000; pp. 1210-1216; vol. 92 No. 15; Journal of National Cancer Institute.
Markus Riessland et al.,; The benzamide M344, a novel histone deacetylase inhibitor. . . ; Journal; Apr. 9, 2006; pp. 101-110; Springer-Verlag.
Makoto Minamiyama et al., ; Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy; Journal; Apr. 21, 2004; vol. 13, No. 11; pp. 1183-1192; Human Molecular Genetics, Oxford University Press.
John P Alao et al.,; Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin DI degradation in MCF-1 breast cancer cells; Journal; Feb. 20, 2006; pp. 1-11; BioMed Central Ltd.
Written Opinion for Application No. 07116430.5, (2009).
Toshio Fukai et al. Cytotoxic Activity of Low Molecular Weight Polyphenols against Human Oral Tumor Cell Lines, Anticancer Research, 2000, pp. 2525-2536, vol. 20.
Chia-Nan Chen et al., Cornpanson of Radical scavenging Activity, Cytotoxic Effects and Apoptosis Induction in Human Melanoma Cells by Taiwanese Propolis from Different Sources, Evidenced-based Complementary and Alternative Medicine, Aug. 18, 2004, pp. 175-185, vol. 1, Issue 2.
European Search Report for application No. 07116430.5, (2009).
Response to the Communication pursuant to Article 94(3) dated Dec. 2, 2009 for Application No. EP07116430.5.
Chen Chia-Nan
Chi Li-Ling
Huang Chih-Hsiang
Huang Chung-Yang
Huang Wei-Jan
Dentz Bernard
King Anthony
Naturewise Biotech and Medicals Corporation
WPAT, P.C.
LandOfFree
Compounds for the inhibition of histone deacetylase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the inhibition of histone deacetylase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the inhibition of histone deacetylase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633442